Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation

Vaccine

Volumn 26, Issue 2, 2008, Pages 185-192

  LeBlanc, Ralph ^a   Vasquez, Yessika ^a   Hannaman, Drew ^b   Kumar, Nirbhay ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Ichor Medical Systems Inc   (United States)

Author keywords

DNA vaccine; In vivo electroporation; Malaria; Transmission blocking vaccine

Indexed keywords

ANTIBODY; DNA VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; MALARIA VACCINE; PARASITE ANTIGEN; PROTEIN PFS25; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG DOSE COMPARISON; DRUG POTENCY; ELECTROPORATION; FEMALE; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VIVO STUDY; MOUSE; NONHUMAN; PARASITE TRANSMISSION; PLASMID; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY AFFINITY; CULICIDAE; ELECTROPORATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; PARASITEMIA; PLASMIDS; PROTOZOAN PROTEINS; VACCINES, DNA;

EID: 37249047376     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.10.066     Document Type: Article

References (39)

1. Snow R.W., Guerra C.A., Noor A.M., Myint H.Y., and Hay S.I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434 (2005) 214-217
2. Kumar N. A vaccine to prevent transmission of human malaria: a long way to travel on a dusty and often bumpy road. Curr Sci 92 (2007) 1535-1544
3. Carter R. Transmission blocking malaria vaccines. Vaccine 19 (2001) 2309-2314
4. Stowers A., and Carter R. Current developments in malaria transmission-blocking vaccines. Expert Opin Biol Ther 1 (2001) 619-628
5. Bruce M.C., Alano P., Duthie S., and Carter R. Commitment of the malaria parasite Plasmodium falciparum to sexual and asexual development. Parasitology 100 (1990) 191-200
6. Kaslow D.C., Quakyi I.A., Syin C., Raum M.G., Keister D.B., Coligan J.E., et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 333 (1988) 74-76
7. Kaslow D.C., Bathurst I.C., Lensen T., Ponnudurai T., Barr P.J., and Keister D.B. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect Immun 62 (1994) 5576-5580
8. Lobo C.A., Dhar R., and Kumar N. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Infect Immun 67 (1999) 1688-1693
9. Coban C., Philipp M.T., Purcell J.E., Keister D.B., Okulate M., Martin D.S., et al. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations. Infect Immun 72 (2004) 253-259
10. Zou L., Miles A.P., Wang J., and Stowers A.W. Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials. Vaccine 21 (2003) 1650-1657
11. Sheerlink J.-P.Y. Genetic adjuvants for DNA vaccines. Vaccine 19 (2001) 2647-2656
12. Sasaki S., Takeshita F., Xin K., Ishii N., and Okuda K. Adjuvant formulations and delivery systems for DNA vaccines. Methods 31 (2003) 243-254
13. Kendall M. Engineering of needle-free physical methods to target epidermal cells for DNA vaccination. Vaccine 24 (2006) 4651-4656
14. Drape R., Macklin M., Barr L., Jones S., Haynes J., and Dean H. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24 (2006) 4475-4481
15. Hermanson G., Whitlow V., Parker S., Tonsky K., Rusalov D., Ferrari M., et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. PNAS 101 (2004) 13601-13606
16. Sedegah M., Rogers W.O., Belmonte A., Belmonte M., Banania G., Patterson N., et al. Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine 24 (2006) 1921-1927
17. O'Hagan D., Singh M., and Ulmer J. Microparticles for the delivery of DNA vaccines. Immunol Rev 199 (2004) 191-200
18. Mollenkopf H., Dietrich G., Fensterle J., Grode L., Diehl K., Knapp B., et al. Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine 22 (2004) 2690-2695
19. Luxembourg A., Hannaman D., Ellefsen B., Nakamura G., and Bernard R. Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine 24 (2006) 4490-4493
20. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V.D., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 81 (2007) 5257-5269
21. Tsang C., Babiuk S., Van Drunen Littel-van den Hurk S., Babiuk L.A., and Griebel P. A single DNA immunization in combination with electroporation prolongs the primary immune response and maintains immune memory for six months. Vaccine 30 (2007) 5485-5494
22. Otten G., Schaefer M., Doe B., Liu H., Srivastava I., zur Megede J., et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22 (2004) 2493-2498
23. Dobano C., Widera G., Rabussay D., and Doolan D. Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation. Vaccine 25 (2007) 6635-6645
24. Peng B., Zhao Y., Xu L., and Xu Y. Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity. Vaccine 25 (2000) 2064-2073
25. Cheung Y.K., Cheng S.C., Sin F.W., and Xie Y. Plasmid encoding papillomavirus Type 16 (HPV 16) DNA constructed with codon optimization improved the immunogenicity against HPB infection. Vaccine 23 (2004) 629-638
26. Li Z., Zhang H., Fan X., Zhang Y., Huang J., Liu Q., et al. DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccine in mice and non-human primates. Vaccine 24 (2006) 4565-4568
27. Hebel H., Attra H., Khan A., and Draghia-Akli R. Successful parallel development and integration of a plasmid-based biologic, container-closure system and electrokinetic delivery device. Vaccine 24 (2006) 4607-4614
28. Tjelle T., Salte R., Mathiesen I., and Kjeken R. A novel electroporation device for gene delivery in large animals and humans. Vaccine 24 (2006) 4667-4670
29. Pullen G., Fitzgerald G., and Hosking C. Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods 86 (1986) 83-87
30. Ifediba T., and Vanderberg J.P. Complete in vitro maturation of Plasmodium falciparum gametocytes. Nature 294 (1981) 364-366
31. Miura K., Keister D.B., Muratova O.V., Sattabongkot J., Long C.A., and Saul A. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs 25 is a direct and predictable function of antibody titer. Malar J 6 (2007) 107-120
32. Miles A.P., Zhang Y., Saul A., and Stowers A.W. Large scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials. Protein Exp Purif 25 (2002) 87-96
33. Malkin E.M., Durbin A.P., Diemert D.J., Sattabongkot J., Wu Y., Miura K., et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23 (2005) 3131-3138
34. Kongkasuriyachai D., Bartels-Andrews L., Stowers A., Collins W.E., Sullivan J., Sattabongkot J., et al. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy. Vaccine 22 (2004) 3205-3213
35. Donnelly J.J., Wahren B., and Liu M.A. DNA vaccines: progress and challenges. J Immunol 175 (2005) 633-639
36. Liu M.A., and Ulmer J.B. Human clinical trials of plasmid DNA vaccines. Adv Genet 55 (2005) 25-40
37. http://www.abedia.com/wiley/record_detail.php?ID=395, Clinical Trials Worldwide, Trial ID: UK-112, 2007.
38. http://www.ClinicalTrials.gov, NIH Clinical Trials website, Identifier:NCT00250419, 2007.
39. http://www.ClinicalTrials.gov, NIH Clinical Trials website, Identifier: NCT00471133, 2007.